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Group 3 innate lymphoid cells (ILC3s) are defined
by the expression of the transcription factor RORgt,
which is selectively required for their development.
The lineage-specified progenitors of ILC3s and their
site of development after birth remain undefined.
Here we identified a population of human CD34+ he-
matopoietic progenitor cells (HPCs) that express
RORgt and share a distinct transcriptional signature
with ILC3s. RORgt+CD34+ HPCs were located in
tonsils and intestinal lamina propria (LP) and selec-
tively differentiated toward ILC3s. In contrast,
RORgtCD34+ HPCs could differentiate to become
either ILC3s or natural killer (NK) cells, with differen-
tiation toward ILC3 lineage determined by stem cell
factor (SCF) and aryl hydrocarbon receptor (AhR)
signaling. Thus, we demonstrate that in humans
RORgt+CD34+ cells are lineage-specified progeni-
tors of IL-22+ ILC3s and propose that tonsils and in-
testinal LP, which are enriched both in committed
precursors and mature ILC3s, might represent pref-
erential sites of ILC3 lineage differentiation.
INTRODUCTION
Innate lymphoid cells (ILCs) are comprised of three main groups
of lymphocytes: group 1 ILCs, including natural killer (NK) cells988 Immunity 41, 988–1000, December 18, 2014 ª2014 Elsevier Inc.and ILC1s, group 2 ILC (or ILC2s), and group 3 ILCs. NK cells
express the T-box transcription factors T-bet (TBX21) and Eo-
mesodermin (EOMES), exert cytolytic activity, and produce
interferon-g (IFN-g) in response to cytokines or infected and
transformed cells. Different human and mouse ILC1 populations
have also been more recently described, sharing the expression
of T-bet and IFN-g (Bernink et al., 2013; Fuchs et al., 2013; Klose
et al., 2014). ILC2s, expressing the transcription factor GATA-3,
provide interleukin-13 (IL-13) and IL-5 for the defense against
helminthic infections. Group 3 ILCs, characterized by the
expression of the retinoic acid receptor (RAR)-related orphan re-
ceptor RORgt (RORC), include fetal lymphoid tissue-inducer
(LTi) cells and adult LTi-like cells, also named ILC3s (Spits
et al., 2013; Spits and Cupedo, 2012). Fetal LTi cells drive sec-
ondary lymphoid organ development and secrete IL-17A and IL-
22 (Cherrier and Eberl, 2012). Because of their crucial role in
secondary lymphoid organ formation before birth, LTi develop-
ment has been investigated mainly in fetal mice (Cherrier and
Eberl, 2012), where expression of a4b7 integrin defines cells en-
riched in LTi cell progenitors (Cherrier et al., 2012; Mebius et al.,
2001; Possot et al., 2011; Sawa et al., 2010; Tachibana et al.,
2011; Yoshida et al., 2001). However, ILC3s with LTi-like charac-
teristics are also found after birth, mainly in human and mouse
intestinal lamina propria (LP) as well as in human tonsils (To)
(Spits and Cupedo, 2012). Adult ILC3s are heterogeneous (Spits
and Cupedo, 2012): a fraction of these ILC3s shares the expres-
sion of the natural cytotoxicity receptors (NCRs) NKp46 and
NKp44 (Sivori et al., 1997; Vitale et al., 1998) with NK cells (Cella
et al., 2009; Cupedo et al., 2009; Luci et al., 2009; Sanos et al.,
2009; Satoh-Takayama et al., 2008). Adult ILC3s produce IL-22
and play a role in the defense against pathogens, in epithelial
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disease (Spits and Cupedo, 2012). Because of their important
contribution to immune responses in adult individuals, it is
essential to understand how the pool of ILC3s is maintained
after birth. The adult pool of ILC3s is not the direct progeny of
their fetal counterpart, but rather differentiates from hematopoi-
etic progenitor cells (HPCs) transferred from fetal liver to bone
marrow (BM) (Sawa et al., 2010). In line with this concept, it
was shown that mouse BM a4b7
+CXCR6+ cells can give rise to
ILC3s as well as to NK cells, although with low efficiency (Possot
et al., 2011). Because RORgt is not upregulated in the BM, the
putative ILC3 precursors might migrate very early to the periph-
ery, especially to the intestinal LP, for their terminal differentia-
tion (Cherrier and Eberl, 2012; Possot et al., 2011). NK cell devel-
opment and lineage-specified progenitors have been previously
described (Carotta et al., 2011; Fathman et al., 2011; Freud
et al., 2005, 2006; Miller et al., 1994; Rosmaraki et al., 2001).
Whereas differentiation of all ILCs requires the transcriptional
repressor inhibitor of DNA binding 2 (Id2), fate specification to-
ward different ILC lineages depends on distinct g-chain cyto-
kines, such as IL-7 for ILC3s and IL-15 for NK cells (Spits and
Cupedo, 2012); moreover, environmental cues acting via the
engagement of the aryl hydrocarbon receptor (AhR) are also
required for the postnatal functional program and differentiation
of mouse ILC3s (Kiss et al., 2011; Lee et al., 2012; Qiu et al.,
2012). The developmental relationship between ILC3s and NK
cells has been controversially discussed, especially in humans
(Crellin et al., 2010; Cupedo et al., 2009; Hughes et al., 2009,
2010, 2014; Montaldo et al., 2012). A progenitor committed to
helper-like ILCs, namely ILC1s, ILC2s, and ILC3s, but not to-
ward cytotoxic NK cells has been very recently identified in
mouse fetal liver and adult BM (Constantinides et al., 2014;
Klose et al., 2014) and named ChILP (Klose et al., 2014), or pro-
genitor to all helper-like ILCs, further strengthening the lineage
separation among NK cells and ILC3s. In humans, it was shown
that ILC3s and NK cells can develop from neonatal umbilical
cord blood (UCB) CD34+ cells (Tang et al., 2011). However,
the stages, preferential sites, and signals required to drive
ILC3 differentiation have not been described in adult individuals.
In the present study, we identified a population of human CD34+
HPCs characterized by the expression of RORgt and a global
signature of ILC3-specifying genes, which preferentially differ-
entiated toward IL-22-producing ILC3s, but only poorly toward
NK cells. RORgt+CD34+ HPCs were selectively enriched in hu-
man tonsils and intestinal LP, but were absent in UCB, BM, pe-
ripheral blood (PB), and thymus. Thus, we propose that the
newly identified RORgt+CD34+ HPCs correspond to the human
ILC3 lineage-specified progenitors and that tonsils and intestinal
LP might represent preferential sites of ILC3 development.
RESULTS
CD34+ HPCs from Different Adult Compartments Can
Differentiate toward ILC3s
IL-22-producing ILC3s can be generated from in vitro culture of
human neonatal UCB CD34+ HPCs (Ahn et al., 2013; Tang et al.,
2011). To understand whether CD34+ HPCs detected in different
compartments after birth could differentiate toward ILC3s,
CD34+ HPCs from UCB or from the BM (Figure S1A availableImonline), PB, or tonsils (To) of adult individuals (Figure 1A) were
sorted and analyzed for their ability to differentiate toward
ILC3s, when cultured in the presence of cytokines (stem cell
factor [SCF], FMS-like tyrosine kynase ligand [Flt3L], IL-7,
and IL-15, hereinafter referred to as ‘‘cytokine mix’’). After
20 days, PB and To CD34+ HPCs gave rise to a population of
LinCD34CD56+CD161+ cells (Figure 1B), which was also ob-
tained in UCB and BM CD34+ HPC cultures, although with lower
frequency (Figure S1B). The majority of CD56+CD161+ cells
generated from all CD34+ HPC cultures expressed the ILC3
transcription factor RORgt, whereas only a minor fraction was
positive for the NK cell markers CD94 and Eomes. Expression
of RORgt was mutually exclusive with CD94 or Eomes (Figures
1B and S1B). IL-22- or IFN-g-producing cells could be detected
in all CD34+ HPC cultures after stimulation with PMA, ionomycin,
and IL-23, which represented the most efficient trigger of IL-22
expression (Figure S1C), as also shown for mature ILC3s (Cu-
pedo et al., 2009; Glatzer et al., 2013). IFN-g was produced
by CD94+ cells and was not coexpressed by IL-22+ cells (Figures
1B and S1B). These data indicate that IL-22+ ILC3s can be
generated from adult PB, BM, and To CD34+ HPCs and
represent the majority of LinCD34CD56+CD161+ cells, as
compared to IFN-g+Eomes+CD94+ NK cells.
RORgt+CD34+ HPCs Reside in the Tonsil and
Intestinal LP
We next wanted to clarify whether ILC3 lineage-specified pro-
genitors could be identified among CD34+ HPCs. To this aim,
RORgt expression was analyzed on CD34+ HPCs isolated
from different compartments. RORgt was clearly expressed
by a fraction of To or intestinal LP CD34+ HPCs, but not by
CD34+ HPCs derived from PB, UCB, BM, or thymus (Figures
2A and S2A). Expression of RORgt and CD34 enabled the
identification of three subsets, i.e., RORgt+CD34dim (herein-
after referred to as RORgt+ HPCs), RORgtCD34dim, and
RORgtCD34bright HPCs, which were characterized further (Fig-
ure 2B). All To CD34+ HPCs were positive for CD45RA (Freud
et al., 2005) and displayed differential expression of AC133, a
stem marker of pluripotency, and of CD10, which can be ex-
pressed by common lymphoid progenitors (CLPs), whereas
among CD34dim HPCs only a fraction of cells expressed the
T-NK committed progenitor markers CD2 and CD7. Typical
markers of ILC3, NK, or ILC1 lineages (CD127, NKp44,
NKp46, NKG2D, CD94, Eomes, T-bet, CCR7, CXCR5, or aE in-
tegrin) were absent in all To CD34+ HPC subsets (Figures 2B
and S2B). IL-1 receptor 1 (IL-1R1), CD161, CD117, b7 and a4 in-
tegrins, as well as the a4b7 heterodimer, were higher expressed
on RORgt+ HPCs (Figure 2B). CD117 represented a good
surrogate marker to identify and isolate To RORgt+ HPCs (Fig-
ures 2C and S2C) and was also preferentially expressed on
RORgt+ HPCs isolated from intestinal LP (Figure S2D). Thus,
To CD34+ HPCs were sorted as CD117+(RORgt+)CD34dim,
CD117(RORgt)CD34dim, and CD117(RORgt)CD34bright
cell subsets (Figure S2E) and transcriptome analysis was per-
formed. RORgt+ HPCs clustered separately and displayed a
distinct global signature compared to RORgtCD34+ cells (Fig-
ure 2D). As also confirmed in RT-PCR, RORgt+ HPCs displayed
higher transcription of RORC, KIT, and ID2, slightly enhanced
expression of NFIL3, and similar expression of AHR and TOX,munity 41, 988–1000, December 18, 2014 ª2014 Elsevier Inc. 989
Figure 1. CD34+ HPCs from PB and Tonsils of Adult Individuals Differentiate toward ILC3s
(A) CD34+ HPCs derived fromPB (left) or tonsil (To; right) were analyzed by flow cytometry (FC) ex vivo, after magnetic enrichment for CD34+ cells (MACSsort) and
after FACS sorting (FACSsort) for the expression of lineage (Lin, CD3, CD19, CD14) CD56 and CD34.
(B) FACS-sorted CD34+ HPCs from PB (left) or To (right) were cultured for 20 days with SCF, Flt3L, IL-7, and IL-15 (cytokine mix) and viable cells were analyzed
after gating on total cells (top row) or on LinCD56+CD161+ cells (middle and bottom rows) for the expression of the specified markers. Expression of intracellular
cytokines was measured after 6 hr PMA, ionomycin, and IL-23 stimulation (bottom row). One representative experiment (n = 4) is shown.
See also Figure S1.
Immunity
RORgt+CD34+ HPCs Give Rise to ILC3sas compared to RORgtCD34bright and CD34dim cells (Fig-
ure 2E). Next, we compared the transcriptome signature of
CD34+ HPC subsets to that of ILC3s isolated from the same
tonsils by calculating the Pearson correlation coefficient be-
tween each population. RORgt+ HPCs highly correlated with
the RORgtCD34bright and CD34dim subsets (Figure 3A), as
also shown by their shared expression of CD34, PROM1,
IL3RA, and FLT3 precursor markers, which were very low or
not even detectable in ILC3s (Figure 3B). However, among
CD34+ cell subsets, RORgt+ HPCs displayed the highest corre-
lation to ILC3s (Figure 3A), sharing a large set of gene tran-
scripts, including CXCR6, FAM124B, NCR1 (NKp46), RORC,
ID2, TNFSF11 (RANKL), KIT, CCR6, NCR3 (NKp30), IL2RB,
IL23R, IL1R, and THY1, which were absent or only very low ex-
pressed in RORgt HPC subsets (Figure 3B). Similar results
could also be obtained when the expression of mRNA and/or
of proteins of selected genes was comparatively analyzed in
RORgt+ HPCs and in different CD127hi ILC3 subsets dissected
according to the expression of NKp44 and CD56 (Figures S3A–990 Immunity 41, 988–1000, December 18, 2014 ª2014 Elsevier Inc.S3C; Glatzer et al., 2013). Among many markers differentially
expressed between RORgt+ HPCs and ILC3s, RORgt+ HPCs
did not express CCR6, IL-23R, or receptor activator of nuclear
factor kappa-B ligand (RANKL) on their surface (Figure S3B).
When cytokine transcripts were analyzed, we observed that
RORgt+ HPCs displayed only very low expression of ILC3-asso-
ciated cytokines, such as IL22, IL2, CCL20, and CSF2, and in-
termediate amounts of TNF, LTA, IL26, and LIF mRNA (Figures
3B and S3C). RORgt+ HPCs were exclusively enriched in IL17F
transcripts (Figure 3B). By analyzing cytokine intracellular
expression after stimulation, we observed that production of
IL-17F and IL-17A could be induced selectively in RORgt+
HPCs, whereas tumor necrosis factor (TNF) was expressed
by all CD34+ HPC subsets (Figures 3C and 3D). IL-22, IFN-g,
or IL-2 production could not be detected among CD34+ HPCs
(Figure S3D). In line with their low expression of LTA and LTB
transcripts (Figures 3B and S3C), RORgt+ HPCs did not display
LTi activity as compared to ILC3s, as shown by ICAM1 and
VCAM1 upregulation on mesenchymal stromal cells (MSCs)
Figure 2. Ex Vivo Characterization of CD34+ HPC Subsets from Different Compartments
(A–C) PB and To CD34+ MACS-enriched cells or intestinal LP FACS-sorted CD45+LinCD127 cells were analyzed by FC after further gating on LinCD56 cells
(A), LinCD56CD34+ HPC subsets (B), or LinCD56CD34+ HPCs (C). One representative staining (n = 3–12) is shown; fmo, fluorescence minus one.
(D and E) To CD34+ HPC subsets were FACS sorted as described in Figure S2E.
(D) Microarray analysis of To CD34+ subsets (n = 6). Heatmap of the significantly differentially expressed genes among RORgt+ HPCs, RORgtCD34dim HPCs,
and RORgtCD34bright HPCs after filtering for high-intergroup and low-intragroup variance.
(E) mRNA expression of the indicated genes were analyzed by quantitative RT-PCR (qPCR) and/or by 48.48 Dynamic Array IFCs in the sorted To CD34+ HPC
subsets. Mean fold transcript expression ± SEM is plotted relative to RORgtCD34bright HPC subset, after normalizing to GAPDH (n = 4–9).
See also Figure S2.
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Figure 3. Comparative Analysis of CD34+ HPC Subsets and ILC3s
Derived from Tonsils
(A and B) Microarray analysis of To CD34+ subsets and of ILC3s (n = 6).
(A) Pearson correlation of means of log2-transformed expression values
among the indicated To-derived cell subsets.
(B) Overlay of mean of log2-transformed expression values (circles) on
Z-scores (color-coded heatmap) of selected genes in the indicated cell pop-
ulations as in (A). Circle size depends on the mean value.
(C and D) To CD34+ HPC subsets were stimulated for 6 hr with PMA, ion-
omycin, and IL-23 and intracellular expression of the indicated cytokines was
analyzed by FC. One representative experiment (C) and mean ± SEM of
cytokine-positive cells (D) are shown (n = 6).
(E) Human MSCs were cultured alone (ctr) or cocultured with ex vivo isolated
ILC3s or RORgt+ HPCs, in the presence of 10 ng/ml of IL-7. After 3 days
of culture, expression of ICAM1 and VCAM1 was analyzed by FC on MSCs,
after gating on CD45 viable cells. One representative experiment is depicted
(n = 2).
See also Figure S3.
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992 Immunity 41, 988–1000, December 18, 2014 ª2014 Elsevier Inc.(Figure 3E). Hence, we have identified a population of RORgt+
CD34dim HPCs resident in human To and intestinal LP, sharing
transcriptome signatures with ILC3s but representing a distinct
immature population.
RORgt+ HPCs Represent Lineage-Specified Progenitors
of ILC3s but Not of NK Cells
Our data suggested that RORgt+ HPCs represent lineage-spec-
ified progenitors of ILC3s. To stringently test this hypothesis, we
performed principal-component analysis (PCA) of the transcrip-
tome signatures of CD34+ HPC subsets as well as of ILC3s
and NK cells isolated from the same tonsil (Figure 4A). All cell
populations were clearly separated by plotting the two first prin-
cipal components, PC1 and PC2. CD34+ HPC subsets clustered
together along PC1, with the RORgt ones forming a tighter
group. PC1 described the large differences occurring between
the immature CD34+ HPC subsets, expressing KIAA1305,
MYCN, FLT3, ARHGAP22, C5orf23 (NPR3), EGFL7, and
NPTX2 transcripts (Figure S4A; Toren et al., 2005) versus mature
NK and ILC3 populations, which shared a defined set of
genes, including CFS2, SLAM and CD2 family receptors,
TNFSF14 (encoding LIGHT), CXCR6, CD247 (encoding CD3z
chain), and IL32 (Figure S4B). Conversely, PC2 clearly discrimi-
nated NK cell versus ILC3 lineage and enabled us to appreciate
the close relationship of RORgt+ HPCs to ILC3s and their dis-
tance to NK cells. Indeed, the genes that maximally contributed
to determine negative PC2 values included several ILC3-speci-
fying genes such as RORC, IL23R, IL1R, IL22, and KIT, as well
as genes previously associated with the Th17 cell lineage,
such as IL17RE (Chang et al., 2011), IL4I1, PTNP13, CTSH (Ra-
mesh et al., 2014; Santarlasci et al., 2012), and MCAM
(Brucklacher-Waldert et al., 2009) (Figure 4B). Conversely, pos-
itive PC2 values were mainly driven by NK-cell-specifying
genes, such as GZMB, GZMH, GZMK, IFNG, FCGR3A (CD16),
and KIRs (Figure 4C). Thus, these data indicate that RORgt+
HPCs are related to the ILC3 lineage, but not to the NK cell line-
age. Next, we tested the differentiation potential of RORgt+
HPCs compared to the other RORgt HPC subsets identified
in adult tonsil by culturing each of the sorted populations with
cytokinemix. After 20 days of culture, all CD34+HPC subsets un-
derwent considerable expansion (Figure S5A) and generated
similar proportions of LinCD34CD56+CD161+ cells (Figures
Figure 4. Principal-Component Analysis of Gene Signatures of
CD34+ HPC Subsets, ILC3s, and NK Cells Isolated from Tonsil
Microarray and principal-component analysis (PCA) of the indicated pop-
ulations was performed.
(A) Depicted are the first two principal components (PC1 and PC2) explaining
45.84% of the variation, divided between 35.14% for the first component and
10.70% for the second.
(B and C) Heatmaps of the genes with the strongest negative (B) and positive
(C) effect on the separation of cell populations along the second principal
component (PC2) are depicted.
See also Figure S4.
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Im5A and S5B). CD56+CD161+ cells obtained from RORgt+
HPCs homogenously expressed RORgt, whereas almost no
RORgtEomes+CD94+ cells could be detected (Figures 5A and
5B). Conversely, CD56+CD161+ cells generated from RORgt
(CD34dim or CD34bright) HPCs included a significant proportion
either of RORgt+ or of Eomes+CD94+ cells (Figures 5A, 5B, and
S5B). Only RORgt HPC cultures gave rise to CD56+CD161lo
cells, which were highly enriched in Eomes+ NK cells, but
not in ILC3s (Figure S5C). The differentiation potential of
RORgtCD34dim and CD34bright HPCs was completely over-
lapping, so further results are shown exclusively for RORgt
CD34dim cells, hereinafter referred to as RORgt HPCs. Similar
data were obtained when CD34+ HPC subsets were cultured
with the stromal cell line OP9 (Figure S5D) and this phenotype
was maintained also after 30 days of culture (Figure S5E).
CD56+CD161+ RORgt+ cells generated either from RORgt or
RORgt+ HPC cultures displayed the homogenous phenotype
CD117+RANKL+NKp44hiNKp46loNKG2DCD16T-bet (Fig-
ure 5C), comparable to ILC3s isolated ex vivo (Glatzer et al.,
2013). CD56+CD161+ (or CD56+CD161lo) Eomes+ cells exclu-
sively obtained from RORgt HPCs were NKp46hiNKG2D+
CD16+/T-bet+CD117loRANKLNKp44lo, similar to mature NK
cells (Figures 5C and S5F). Despite the fact that both HPC sub-
sets lost CD34 and underwent comparable number of divisions
during the first 5 days of culture, only a minor fraction of RORgt
HPCs acquired markers of ILC3 or NK cell lineages, whereas
RORgt+ HPCs rapidly developed into mature ILC3s (Figures
5D and S5G). Finally, we performed clonal assays. In cultures
starting with 1 cell/well, proliferation and differentiation toward
LinCD34CD56+CD161+ cells was sustained in 17% and 8%
of wells plated with RORgt+ or RORgt HPCs, respectively (Fig-
ure 5E). Although some CD34+ HPC cultures still gave rise to
a mixed population of ILC3s and NK cells, RORgt+ HPCs mostly
generated cultures containing exclusively ILC3s, whereas
cultures comprising solely NK cells could not be obtained.
Conversely, RORgt HPCs gave rise both to NK cells and to
ILC3s (Figures 5F and 5G). Altogether, these data indicate that
RORgt+ HPCs represent ILC3 lineage-specified progenitors,
whereas RORgt HPCs include ILC3 and NK cell progenitors.
RORgt+ HPCsGiveRise to IL-17- and/or IL-22-Producing
ILC3s
Next, we characterized the cytokine profile of cells derived from
CD34+ HPC cultures. CD56+CD161+ cells derived from both
RORgt and RORgt+ HPC cultures were enriched in IL-22,
IL-2, and TNF, whereas IFN-g-expressing cells could be
observed preferentially among RORgt HPC cultures (Figures
6A, 6B, and S6A). IL-22 production was not detectable amongmunity 41, 988–1000, December 18, 2014 ª2014 Elsevier Inc. 993
Figure 5. CD34+RORgt+ HPCs Differentiate Selectively toward ILC3s
(A–D) To RORgt+ HPCs and To RORgt HPCs were cultured in the presence of cytokine mix for 20 days (A–C) or for 5 days (D) and analyzed by FC.
(A and B) Pie charts (A, left) represent the mean percentage of the indicated cell subsets obtained after gating on LinCD34 cells (n = 13). One representative
experiment (A, right) and mean percentage ± SEM (B) of positive cells after gating on viable LinCD56+CD161+ cells is shown (n = 13).
(C) Expression of the indicatedmarkers was analyzed after gating on LinCD56+CD161+RORgt+ cells (black line) or on LinCD56+CD161+Eomes+ (dark gray line)
generated from RORgt+ or RORgt HPC cultures. One representative experiment is shown (n = 3–13).
(D) Proliferation is shown as overlay of CFSE-labeled RORgt+ HPCs (red) and RORgt HPCs (blue) cultured for 5 days (n = 3).
(E–G) Clonal assay: To RORgt+ and To RORgt HPCs were plated at 100, 50 (6 wells per dilution), 10, 5, 1, or 0.5 HPC/well (96 wells per dilution) and cultured
20 days in the presence of cytokine mix and irradiated OP9 (n = 3).
(E) Culture detection failure, i.e., the percentage of cultures in which HPCs did not proliferate nor differentiate toward LinCD34CD56+CD161+ cells, is plotted as
a function of starting cell number. Mean ± SEM (n = 3).
(F and G) Mean percentage ± SEM of cultures in which HPC subsets differentiated exclusively into ILC3s, into NK cells, or into a mixed population comprising
ILC3s and NK cells. Data are plotted among all cultures obtained (F) or as a function of starting cell number (G).
See also Figure S5.
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cells expressing RANKL, which was a selective marker of
RORgt+EomesCD94 cells (Figures S6B and S6C), as shown994 Immunity 41, 988–1000, December 18, 2014 ª2014 Elsevier Inc.for ILC3s (Cella et al., 2010). ILC3s generated from CD34dim
HPCs not only expressed high amounts of NKp44 (Figures 5C
and S6D), but also responded to NKp44 engagement and to
Figure 6. RORgt+ HPCs Differentiate into IL-17- and/or IL-22-pro-
ducing ILC3s
(A–C) To RORgt+ and To RORgt HPCs were cultured for 20 days with cyto-
kine mix and analyzed by FC for intracellular cytokine expression after 6 hr
stimulation with PMA, ionomycin, and IL-23 and gating on LinCD56+
CD161+cells (A), LinCD56+ (B), or LinCD56+TNF+ (C) cells. One represen-
tative experiment (A) andmean percentage ± SEM of cytokine-positive cells (B
and C) are depicted (n = 8); RORgt+ HPCs shown as red dots; RORgt HPCs
shown as blue triangles.
(D–G) To RORgt+ HPCs were cultured for 5 days with cytokine mix and
analyzed by FC.
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Imstimulation with IL-7, IL-1b, and IL-23 by producing TNF and IL-
22 (Figure S6E), similar to their mature counterpart (Glatzer et al.,
2013). Although IL-17A was produced ex vivo by a fraction of
RORgt+ HPCs, this cytokine could almost not be observed by
day 20 of culture (Figures S6A and S6F). Indeed, IL-17A+ and
IL-17A+IL-22+ cells were enriched among CD56CD161+ cells,
which were detectable only around day 5 (Figures 6D and 6E),
but were lost by day 20 of culture (Figure S6F). This transient
population of CD56CD161+ cells was RORgt+EomesCD94
and displayed similar expression of RANKL and NKp44
compared to its CD56+CD161+RORgt+ counterpart (Figures 6F
and 6G). Altogether, these data show that RORgt+ HPCs give
rise to IL-22-producing ILC3s and to a transient population of
IL-17A-producing ILC3s.
SCF and AhR Signaling Skew ILC3s at Expenses of NK
Cell Development
We next investigated the signals driving the acquisition of mas-
ter transcription factors RORgt or Eomes and differentiation to-
ward ILC3s or NK cells in RORgt HPCs. RORgt HPCs did
not survive in the presence of single cytokines (Figure S7A),
but only with combination of at least two cytokines among
IL-7, IL-15, or SCF, which enabled the generation of CD161+
cells (Figure 7A). Differentiation of ILC3s was supported by
cytokine combinations comprised of SCF (Figure 7B). Although
IL-15 favored acquisition of NK cell differentiation, as
measured by frequency of CD56+CD161lo (Figure 7A) or of
CD94+ (Figure 7C) cells, IL-7 and IL-15 similarly promoted
expression of RORgt, when used in combination with SCF (Fig-
ure 7B). Next, we tested whether AhR signaling could also
contribute to the regulation of ILC3 and/or NK cell develop-
ment, because AhR ligands are present at biologically active
concentration in normal culture medium and can be blocked
by the addition of the specific inhibitor (AhRi) CH-22319 (Veld-
hoen et al., 2009). In line with these data, expression of the
AhR target gene CYP1A1 was upregulated after in vitro culture
of RORgt HPCs with cytokine mix, as compared to ex vivo
isolated cells, and was completely abolished in the presence
of AhRi (Figure S7B). Although cell survival was consistently
impaired when the AhR agonist FICZ was supplemented in cul-
ture (data not shown), addition of AhRi did not influence the to-
tal number of cells recovered (Figure S7C); however, it clearly
modulated their commitment fate. AhRi impaired the expres-
sion of RORgt, CD117, NKp44, and IL-22, while promoting
that of Eomes and CD94 (Figures 7D–7F). AhR blocking did
not impair ILC3 development exclusively via CD117 downregu-
lation (Kiss et al., 2011), as shown by the fact that a further
decrease in RORgt+ ILC3s and increase in Eomes+ NK cells(D) Mean percentage of the indicated subsets gated on LinCD34 cells (pie
chart, left) and one representative experiment gated on viable cells (right) are
depicted (n = 6).
(E) One representative experiment and mean percentage of cytokine-positive
cells ± SEM (n = 6) is shown after 6 hr stimulation with PMA and ionomycin and
IL-23 and gating on LinCD34CD56CD161+ (green) or LinCD34CD56+
CD161+ (yellow) subsets.
(F and G) One representative experiment (F) and mean percentage of positive
cells ± SEM (G) are shown after gating as in (E) (n = 6).
See also Figure S6.
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Figure 7. SCF and AhR Signaling Skew ILC3s at the Expense of NK
Cell Differentiation
(A–H) To RORgt HPCs were cultured for 10 days with the indicated cytokines
or AhR inhibitor (AhRi) and analyzed by FC.
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(Figures 7G and 7H). Altogether, these data show that fate
commitment of human RORgt HPCs toward ILC3s is sup-
ported by SCF and AhR signaling, which promotes RORgt,
NKp44, and CD117 expression while inhibiting differentiation
of Eomes+ NK cells.
AhR Blocking Inhibits Further Differentiation of RORgt+
HPCs toward Mature ILC3s
We next investigated the signals driving further differentiation of
RORgt+ HPCs toward mature RORgt+ ILC3s. IL-15, IL-7, or SCF
could sustain differentiation of RORgt+ HPCs, even when each
cytokine was used alone (Figure 7I), whereas Flt3L was dispens-
able (Figure S7D). IL-15 and IL-7 induced CD56 upregulation on
differentiating CD161+ cells (Figure 7J). In particular, IL-15 pref-
erentially promoted the differentiation of RORgt+ HPCs toward
CD56+CD161+ cells, SCF mainly toward CD56CD161+ cells,
and IL-7 equally toward both populations. However, IL-7 and
SCF also supported the survival of CD56CD161 cells (Fig-
ure 7I). All cytokines induced with different efficiencies the acqui-
sition of NKp44 and IL-22 (Figure 7J), which was significantly
regulated by the AhR signaling (Figures 7K and S7E), in line
with what we observed in RORgt HPC cultures. Moreover,
AhR blocking induced partial downregulation of CD117 but did
not drastically influence RORgt expression nor promoted the
acquisition of CD94 (Figures 7L and S7F). Altogether, these
data show that cytokines and AhR signaling can modulate the
differentiation of lineage-specified RORgt+ HPCs toward mature
ILC3s.
DISCUSSION
Previous studies have enlightened fetal development of mouse
LTi (Cherrier and Eberl, 2012). More recently, it was proposed(A) Mean percentage of the indicated cell subsets gated on LinCD34 cells
(pie chart) (n = 7).
(B and C) Mean percentage of RORgt+ cells ± SEM after gating on
LinCD34CD161+ (B) and of CD94+ cells ± SEM after gating on
LinCD34CD56+CD161lo cells (C) (n = 6).
(D–F) One representative experiment (D) and mean percentage of positive
cells ± SEM or of MFI ratio (geometrical MFI of AhRi-treated cells versus
geometrical MFI of untreated cells) ± SEM (E and F) are shown (n = 6). Cells
were analyzed after gating on LinCD34CD161+ cells. Intracellular IL-22
expression was measured by FC after 6 hr stimulation with PMA, ionomycin,
and IL-23 (F).
(G and H) Cells were cultured either with cytokine mix or with IL-15, IL-7, Flt3L
(‘‘w/o SCF’’), and AhRi. One representative experiment (G) and mean per-
centage of positive cells ± SEM (H) are shown (n = 6). Cells were analyzed after
gating on LinCD34CD161+ cells.
(I–L) To RORgt+ HPCs were cultured for 5 days with the indicated cytokines or
AhRi and analyzed by FC.
(I) Pie charts depict mean percentage of the indicated subsets among
LinCD34 cells (n = 6).
(J) Mean percentage of positive cells ± SEM is shown after gating on
LinCD34CD161+ cells (n = 6).
(K and L) Mean percentage of positive cells or MFI ratio ± SEM (geometrical
MFI of AhRi-treated cells versus geometrical MFI of untreated cells), are
shown, respectively (n = 6). Intracellular IL-22 expression (J and K) was
measured by FC after 6 hr stimulation with PMA, ionomycin, and IL-23.
See also Figure S7.
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RORgt+CD34+ HPCs Give Rise to ILC3sthat the adult pool of ILC3s ismaintained via differentiation of BM
precursors (Cherrier and Eberl, 2012; Constantinides et al., 2014;
Klose et al., 2014; Possot et al., 2011; Sawa et al., 2010). In line
with these data, we here demonstrated that human BM, PB, and
To CD34+ HPCs from adult individuals can differentiate toward
ILC3s. More importantly, the present description of RORgt+
HPCs represents the identification and extensive characteriza-
tion of human ILC3 lineage-specified progenitors, enlightening
several unclear aspects of ILC3 and NK cell development.
Despite their overall close similarity to other CD34+ cells, RORgt+
HPCs shared with mature ILC3s a broad transcriptome signa-
ture, marking their close lineage relation to ILC3s and their
distance to NK cells. Notably, RORgt+ HPCswere selectively en-
riched in human To and intestinal LP but were excluded fromBM,
PB, and thymus. In line with our observation, it was shown that
ILC3 progenitors expressing RORgt are also absent in mouse
BM and that RORgt acquisition might rather occur in the LP
(Cherrier and Eberl, 2012; Possot et al., 2011). Altogether these
data indicate that To and intestinal LP, but not BM, might repre-
sent privileged sites of human ILC3 differentiation. An overlap-
ping subset of To CD34+ HPCs (CD117+CD94CD34+) originally
described as ‘‘stage II NK cells’’ was shown to differentiate, upon
IL-15 culture, toward CD117+CD56+CD34 cells (defined as
‘‘stage III NK cells’’). In that study, CD94 upregulation could be
observed only on a very rare fraction of cells (Freud et al.,
2006). It was later shown that most stage III NK cells rather corre-
spond to mature NCR+ ILC3s (Crellin et al., 2010; Tang et al.,
2011). On the same line and in extension of those data, we
showed here that CD117+CD34dim HPCs express RORgt and
only a very rare fraction of these cells acquire CD94 and Eomes
expression, whereas almost all cells give rise to IL-22-producing
ILC3s, also in clonal assays. The small fraction (%2%, even at
day 30) of RORgtEomes+CD94+ cells generated from cultures
of RORgt+ HPCs (sorted as CD117+CD34dim cells) probably
derived from a contamination with RORgt cells, which repre-
sented around 10% of the CD117+CD34dim starting population.
Thus, in light of the present findings, To CD117+CD34dim HPCs
should not be considered, at least in their largemajority, as stage
II NK cells, but rather as ILC3 lineage-specified progenitors.
However, we would like to stress that, although CD117 is a
good surrogate marker to sort RORgt+ HPCs from tonsils and
gut LP, it can also be expressed in CD34+ HPCs isolated from
other compartments, in linewith its central role in hematopoiesis.
Thus, ILC3 lineage-specified progenitors should be defined not
according to the expression of CD117, but by that of RORgt,
which is confined to tonsils and gut LP CD34+ HPCs. Two recent
reports have identified human IFN-g-producing group 1 ILCs,
which are distinct from NK cells, because they express CD103
(aE integrin) (Fuchs et al., 2013) or lack CD56 and CD94 (Bernink
et al., 2013). Moreover, it was shown that mouse NCR+RORgt+
ILC3s are Eomes but express T-bet and low IFN-g (Klose
et al., 2013; Rankin et al., 2013; Sciume´ et al., 2012); conversely,
human NCR+RORgt+ ILC3s isolated ex vivo do not express T-
bet, Eomes, or IFN-g (Cella et al., 2009; Glatzer et al., 2013).
Because Eomes+ cells generated in our cultures coexpressed
CD56, CD94, T-bet, NKp46, and NKG2D (see Figures 5C and
S5F) and did not express CD103 (data not shown), we think
that it is reasonable to consider them NK cells. However, at
this stage, we cannot exclude that other group 1 ILCs might beImgenerated in our cultures. Only the identification of additional
markers will enable a clear dissection among potentially different
human group 1 ILC subsets. In line with the poor ability of To
CD117+CD34+ HPCs to differentiate toward B cells or T cells
(Freud et al., 2006), we could reasonably exclude the possibility
that RORgt+CD34+ HPCs represent T cell precursors, because
thymic CD34+ HPCs did not express RORgt (Figure S2A).
Indeed, RORgt is expressed during T cell development only at
the CD4+CD8+ double-positive stage (Eberl and Littman, 2004;
Sun et al., 2000). In contrast to RORgt+ HPCs, To RORgt
HPCs remain a quite undefined and probably heterogeneous
population of precursors. RORgtHPCsmight be potentially en-
riched of one single common ‘‘ILC lineage-specified progenitor,’’
retaining differentiation potential toward ILC3s, NK cells, and all
other ILC lineages; however, we cannot completely exclude the
possibility that RORgt HPCs are partially contaminated with
CLP-like populations. Further characterization of RORgt HPC
subsets in BM and in tissues will help to clarify these unsolved
issues and to possibly identify the human equivalent of the mu-
rine ChILP as well as the putative common ILC lineage-specified
progenitor. Distinct cytokines promote the differentiation toward
ILC3s or NK cells. SCF was crucial to induce differentiation of
RORgt HPCs toward ILC3s, thereby further supporting a cen-
tral role of this cytokine in ILC3 development (Chappaz et al.,
2010). Conversely, IL-7 and IL-15 similarly contributed to ILC3
development, at least when added in vitro in combination with
SCF. Ahr/ mice have dramatically reduced numbers of ILC3s
and it was shown that AhR signaling promotes mouse ILC3 dif-
ferentiation, maintenance, and function (Kiss et al., 2011; Lee
et al., 2012; Qiu et al., 2012). In our study, we show that AhR
signaling acts at different steps—both before and after RORgt
acquisition—to induce commitment of human RORgt HPCs to-
ward ILC3 lineage and to modulate the phenotype of mature
ILC3s generated from RORgt+ HPCs. Blocking of the AhR
signaling did not only function via downregulation of CD117, in
line with previous data (Kiss et al., 2011), but promoted ILC3 dif-
ferentiation at the expense of the NK cell lineage also in the
absence of SCF. Although the role of Notch signaling in mouse
fetal and adult ILC3 development has been controversially
debated (Cherrier et al., 2012; Possot et al., 2011), we show
that ILC3 differentiation from human CD34+ HPCs can efficiently
occur also in the absence of external provision of Notch
signaling. One interesting feature of To RORgt+ HPCs is that
they express IL-17. Although IL-17 can be produced by certain
ILC3 subsets (preferentially human CD56 ones) under inflam-
matory conditions (Buonocore et al., 2010; Geremia et al.,
2011), its expression at steady state is mostly restricted to fetal
LTi, and it decreases in adult ILC3s and is absent in To CD56+
NKp44+ ILC3s (Glatzer et al., 2013; Hoorweg et al., 2012;
Sawa et al., 2011). Here we show that, after in vitro differ-
entiation, IL-17 expression was strongly enriched among
CD56CD161+ cells, which transiently appeared around day 5,
especially in the presence of SCF. Conversely, IL-17 production
was almost lost among IL-22-producing CD56+CD161+ cells,
which was the dominant population at later time points, espe-
cially in the presence of IL-15 or IL-7. Thus, IL-17 expression
might represent either a transient feature of ILC3 development
or a hallmark of a distinct CD56 ILC3 subset. In conclusion,
our data provide characterization of human RORgt+CD34+munity 41, 988–1000, December 18, 2014 ª2014 Elsevier Inc. 997
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human tonsils and intestinal LP as potential sites of ILC3
development.
EXPERIMENTAL PROCEDURES
Cell Isolation and Cultures
PB leukocyte concentrates, UCB, and samples derived from different tissues
were used. The relevant institutional review boards approved the study and all
patients gave their written informed consent according to the Declaration of
Helsinki. Further details about sample source and cell isolation procedures
are included in the Supplemental Information. To perform phenotypic and
functional analysis, CD34+ cells from PB, UCB, BM, To, and thymus were en-
riched by magnetic cell sorting (MACS) with the CD34-progenitor cell isolation
kit (Miltenyi Biotec), and phenotypic analysis on intestinal LP CD34+ HPCs was
performed on FACS-sorted CD45+LinCD127 cells. Sorting strategies used
to perform differentiation cultures, stimulation, microarray, and PCR analysis
are described in the Supplemental Information. 2 3 103 FACS-sorted CD34+
cells were cultured in round bottom 96-well plates (BD) with RPMI-1640 me-
dium supplemented with 10% human AB serum, 2 mM L-Glutamin (Lonza),
100 U/ml penicillin, 0.1 mg/ml streptomycin, SCF, Flt3L, IL-7, and IL-15 (all
50 ng/ml) (Miltenyi) and, where indicated, were cultured in the presence of
g-irradiated OP9 cells (ATCC) or AhR inhibitor CH-22319 (Sigma). Further de-
tails are provided in the Supplemental Information.
Flow Cytometry and Intracellular Cytokine Analysis
For detection of intracellular cytokine expression, cells were stimulated 6 hr
at 37C with BrefeldinA (10 mg/ml) for the last 5 hr. Cells were stimulated
with either PMA (25 ng/ml) and ionomycin (1 mg/ml) (both Sigma) and
IL-23 (50 ng/ml; Miltenyi Biotec) (P+I+IL23), with IL-23 and IL-7 and IL-1b
(50 ng/ml), or with anti-Biotin MACSiBead particles loaded with biotinylated
anti-NKp44 mAb (Miltenyi Biotec), as previously described (Glatzer et al.,
2013). Data were acquired on FACSCanto II (BD Biosciences) or Gallios (Beck-
man Coulter) flow cytometers and analyzed with FlowJo software (Tree Star). A
list of mAbs used in the study is included in the Supplemental Information.
Quantitative RT-PCR and Microarray Analysis
mRNA transcript levels were analyzed by RT-PCR and/or by 48.48 Dynamic
Array Integrated Fluidic Circuits (IFCs) (Fluidigm). Global gene expression
was assessed by Agilent Whole Human Genome Oligo Microarrays 8X60K
v2 (Agilent Technologies). RNA extraction, hybridization, feature extraction,
background correction, and normalization were performed by Miltenyi
Genomic Services and Bioinformatics Department. Further details about the
procedures have been included in the Supplemental Information.
Statistical Analysis
Data were analyzed with GraphPad Prism 6 software. To determine statistical
significance, Wilcoxon matched paired test was used for all experiments: *p%
0.05; **p% 0.01; ***p% 0.001; ****p% 0.0001. Microarray data were analyzed
with R v.3.0.1. Further details about the procedure have been included in the
Supplemental Information.
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The raw as well as log2-transformed normalized values are available under the
GEO accession number GSE63197.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
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